



NDA 201023/S-011

**SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING
REQUIREMENTS**

Sanofi US Services Inc.
Attention: Donna Supko, Ph.D
Senior Director, Regulatory Affairs
500 Kendall Street
Cambridge, MA 02142

Dear Dr. Supko:

Please refer to your Supplemental New Drug Application (sNDA) dated October 25, 2013, received October 25, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for JEVTANA[®] (cabazitaxel) Injection.

We acknowledge receipt of your amendments dated January 24, March 27, April 3, July 30, September 10, October 16, and October 28, 2014.

This “Prior Approval” supplemental new drug application proposes changes to the Highlights of Prescribing Information, Dosage and Administration, Drug Interactions, and Clinical Pharmacology section of the Prescribing Information, as well as revisions to the Patient Package Insert, based on data obtained from the TCD10870 study: “A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cabazitaxel in Combination with Cisplatin Administered every 3 Weeks in Patients with Advanced Solid Malignancies”.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being

Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We have received your submission dated October 25, 2013, containing the final report for the following postmarketing requirements listed in the June 17, 2010, approval letter.

- 1649-7 Conduct a drug interaction trial to evaluate the effect of a strong CYP3A4 inhibitor (e.g., ketoconazole) on the pharmacokinetics of cabazitaxel in cancer patients.
- 1649-8 Conduct a drug interaction trial to evaluate the effect of a strong CYP3A inducer (e.g., rifampin) on the pharmacokinetics of cabazitaxel in cancer patients.

We have reviewed your submission and conclude that the above requirements were fulfilled.

We remind you that there are postmarketing requirements listed in the June 17, 2010, approval letter that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Charlene Wheeler, Regulatory Project Manager, at (301) 796-1141.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.
Acting Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
11/19/2014